Mapping Alzheimer Biomarkers for Context of Use With the FDA BEST (Biomarkers, Endpoints, and other Tools) Guidance

Time: 11:45 am
day: Day Two


  • Applying biomarkers to Alzheimer’s Disease (AD) can be done in the context of the Amyloid, Tau, Neurodegeneration (ATN) framework, which can be used for diagnosis and staging, but has a complex relationship to cognition or clinical measures.
  • Biomarkers for prediction, prognosis and risk are increasingly being assessed in longitudinal studies, with the goals of facilitating early diagnosis and intervention.
  • Pharmacodynamic and surrogate markers are a challenge in the context of AD